TipRanks
Go Ultimate55% OFF

SRx Health Solutions (SRXH) AI Stock Analysis

SRXH

SRx Health Solutions

(NYSE MKT:SRXH)

Select Model
Rating:44Neutral
Price Target:$0.98â–¼(-2.97% Downside)
Action:reiterated
Date:10/08/26

The score is held down primarily by weak and volatile financial performance (losses and deep negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation is only modestly supportive due to a dividend despite unprofitable earnings, while corporate events are a relative positive (compliance restored, buyback/dividend, strategic initiatives) but do not offset the core earnings-and-cash risks.

Positive Factors
Improved TTM capitalizationZero reported debt and a large equity base materially reduce near-term solvency pressure and give SRx greater flexibility to fund operations or pursue strategic initiatives. This improvement strengthens resilience over the next several quarters, although shareholder returns remain weak.
Negative Factors
Deeply negative free cash flowDeeply negative free cash flow indicates that current operations are not funding required investment and may continue to consume cash. Repeated negative operating cash flow in several annual periods reinforces the risk that SRx will need external financing to sustain or expand the business.

SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%SRXH-93.56%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$9.94M
Dividend Yield
4.95%
Average Volume (3M)
734.36K
Price to Earnings (P/E)
-0.0
Beta (1Y)
-0.06
Revenue Growth
―
EPS Growth
―
Country
US
Employees
7
Sector
Consumer Defensive
Sector Strength
62
Industry
Software - Application

SRx Health Solutions Business Overview & Revenue Model

Company Description

SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.

SRx Health Solutions Earnings Call Summary

Earnings Call Date:Mar 26, 2025(Q4-2024)|% Change Since:-99.07%|Next Earnings Date:Jun 24, 2020
Earnings Call SentimentPositive

The earnings call highlighted significant improvements in profitability measures, including gross profit margins, net loss, and EBITDA. Revenue growth, particularly in the fourth quarter and international markets, was strong. However, there were challenges such as a decline in annual net revenues and ongoing EBITDA losses. Overall, the company's strategic pivots and financial health improvements contributed to a positive outlook.

Positive Updates

Improved Gross Profit Margin
The company reported a gross profit margin of 37% for the full year, representing an increase of over 600 basis points.

Negative Updates

Decline in Annual Net Revenues
Annual net revenues were down 9% due to strategic exits from non-core sales channels and the closure of an unprofitable direct-to-consumer business.

Company Guidance

In the fourth quarter of 2024, Better Choice Company reported notable financial achievements and strategic advancements. The company delivered a gross profit margin of 37%, improving by over 600 basis points year-over-year, and adjusted EBITDA loss was reduced by 78% to approximately $1.9 million on annual net revenues of $35 million. The company experienced a 26% increase in fourth-quarter revenue, driven by 32% growth on platforms like Amazon and Chewy, and 18% international growth. Key operational improvements included a 22% reduction in SG&A expenses and a more than 40% reduction in inventory, leading to a working capital position of $7.9 million. Additionally, Better Choice successfully negotiated a $6.2 million gain from extinguishing debt and accounts payable. The company's focus on e-commerce channels is expected to continue propelling growth into 2025, as evidenced by the profitability improvements and strategic exits from non-core sales channels. Looking forward, Better Choice is poised for expanded growth through its acquisition of SRx Health Solutions, which is anticipated to close in April, further solidifying its position as a leader in the pet health and wellness sector.

SRx Health Solutions Financial Statement Overview

Summary

Overall fundamentals are weak: income statement results are inconsistent and largely loss-making, and cash flow quality is a major concern with deeply negative free cash flow and unreliable operating cash flow. The TTM balance sheet looks improved with zero reported debt, but prior leverage volatility and weak returns on equity reduce confidence in financial stability.

Income Statement

28Negative

Balance Sheet

50Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMSep 2025Dec 2024Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue-37.41M6.53M50.30M161.55M92.63M58.63M
Gross Profit-12.16M1.53M18.49M32.07M13.31M17.47M
EBITDA-7.05M-7.98M6.40M-9.67M1.01M10.58M
Net Income-40.42M-45.01M-241.60K-15.13M-2.45M3.80M
Balance Sheet
Total Assets145.36M8.40M22.72M42.05M34.79M98.67M
Cash, Cash Equivalents and Short-Term Investments49.69M1.31M6.41M2.07M1.66M36.89M
Total Debt04.47M2.02M39.38M17.85M13.16M
Total Liabilities2.37M8.00M120.62M70.80M33.86M24.91M
Stockholders Equity142.99M407.00K13.91M15.08M62.20M73.76M
Cash Flow
Free Cash Flow-8.36M-8.14M-5.97M79.00K-20.75M-15.56M
Operating Cash Flow101.00K-8.14M-5.91M97.00K-20.55M-15.11M
Investing Cash Flow-34.47M5.91M-3.06M-18.00K-198.00K-449.89K
Financing Cash Flow79.09M12.17M7.08M-5.10M1.28M47.36M

SRx Health Solutions Technical Analysis

Technical Analysis SentimentNegative
Last Price1.01

Price Trends

50DMA1.49Negative
100DMA2.48Negative
200DMA5.06Negative

Market Momentum

MACD-0.15Positive
RSI24.73Positive
STOCH23.76Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRXH, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.49, and below the 200-day MA of 5.06, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 24.73 is Positive, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRXH.

SRx Health Solutions Risk Analysis

SRx Health Solutions disclosed 96 risk factors in its most recent earnings report. SRx Health Solutions reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

SRx Health Solutions Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

SRXH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GRFSGRFS71Outperform$7.31B16.388.43%3.48%6.84%61.67%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
OGNOGN53Neutral$3.63B17.5222.11%0.58%-3.21%-58.19%
SRXHSRXH44Neutral$20.39M-0.01-97.77%4.95%――
CTORCTOR42Neutral$51.51M-1.16-102.97%―――

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%100%SRXHGRFSSCLXOGNCTORMIRADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
SRXH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SRXHSrx Health Solutions Inc.1.01-16.89-94.36%
GRFSGrifols SA8.10-1.23-13.16%
SCLXScilex Holding Company1.85-9.27-83.36%
OGNOrganon & Co.13.847.18107.96%
CTORCitius Oncology, Inc.0.55-1.12-66.83%
MIRAMIRA Pharmaceuticals, Inc.0.55-1.15-67.76%

SRx Health Solutions Corporate Events

Business Operations and StrategyM&A Transactions

SRx Health Solutions to Acquire CERo Therapeutics Subsidiary

Positive
Oct 7, 2026

On October 6, 2026, SRX Global Inc. entered into a Stock Purchase Agreement to acquire all outstanding shares of CERo Therapeutics, Inc. from CERo Therapeutics Holdings, Inc., with CERo becoming a wholly owned subsidiary at closing. The consideration...

Business Operations and StrategyDividendsProduct-Related Announcements

SRx Launches AI-Powered Actively Managed ETF Platform

Positive
Oct 6, 2026

On October 6, 2026, SRX Global Inc. announced it is committing $1.5 million to launch a family of actively managed, AI-powered exchange traded funds through its EMJX platform, in partnership with Kupa AI and its co-founder Andy Kim. The ETF family wi...

Business Operations and StrategyStock BuybackPrivate Placements and Financing

SRx Health Solutions Announces Stock Repurchase Plan Amendment

Positive
Sep 9, 2026

On August 27, 2026, SRX Global Inc. entered into a Securities Purchase Agreement with accredited investors, under which the buyers acquired 3,579 shares of Series C convertible preferred stock for an aggregate $2.825 million, with the securities conv...

Business Operations and StrategyPrivate Placements and Financing

SRx Health Solutions Secures Major CERo Financing Deal

Positive
Sep 2, 2026

On August 31, 2026, SRX Global Inc. announced it had acquired senior secured debt in CERo Therapeutics Holdings, consolidating prior convertible notes and providing up to $11.67 million in financing, backed by first-priority liens on CERo’s equ...

Private Placements and FinancingRegulatory Filings and Compliance

SRx Health Solutions Completes Series C Preferred Financing

Positive
Aug 28, 2026

On August 27, 2026, SRX Global Inc. entered into a private placement Securities Purchase Agreement with accredited investors, issuing 3,579 shares of Series C convertible preferred stock for $2.86 million, paid via assignment of CERO Therapeutics Hol...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026